Total buying$00 buys
IMVT
Immunovant, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$356k5 sells
Net open-market−$356kBuying minus selling
Active insiders4Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 09, 2026
Open-market transaction mix · 5 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 5 | 0 | $0 | $356k | -$356k |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (4)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- VE-$1.7M
- SS-$122.1k
- GM-$71.8k
- VC-$42.5k
IMVT transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
IMVTImmunovant, Inc. | Stout Jay SCTO | S · saleSEC filing ↗ | -$51.1kView disclosure → | |
IMVTImmunovant, Inc. | Stout Jay SCTO | S · saleSEC filing ↗ | -$70.9kView disclosure → | |
IMVTImmunovant, Inc. | Van Tuyl ChristopherCLO | S · saleSEC filing ↗ | -$42.5kView disclosure → | |
IMVTImmunovant, Inc. | Gloria MelanieCOO | S · saleSEC filing ↗ | -$71.8kView disclosure → | |
IMVTImmunovant, Inc. | Venker EricCEO | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
IMVTImmunovant, Inc. | Venker EricCEO | S · saleSEC filing ↗ | -$119kView disclosure → | |
IMVTImmunovant, Inc. | Venker EricCEO | D · returnSEC filing ↗ | -$2.89MView disclosure → | |
IMVTImmunovant, Inc. | Venker EricCEO | M · exerciseSEC filing ↗ | $1.33MView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period8transactionstxns
- S · Open-market sells · dominant5 · 63%
- M · Option exercise2 · 25%
- D · Issuer dispositions1 · 13%
Activity by reported role
A joint filing can contribute to multiple rolesChief executive officer4
CTO2
CLO1
COO1
Reported Holdings After
Separated by insider, security, and ownership type
Venker EricCommon Stock · Direct
257,075Oct 02, 2026
Stout Jay SCommon Stock · Direct
201,532Oct 07, 2026
Venker EricCapped Value Appreciation Rights · Direct
921,875Oct 01, 2026
Gloria MelanieCommon Stock · Direct
217,060Oct 07, 2026
Van Tuyl ChristopherCommon Stock · Direct
175,218Oct 07, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Immunovant, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Immunovant, Inc.?
Stout Jay S, Van Tuyl Christopher, Gloria Melanie, Venker Eric.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Stout Jay S reported a sale on Oct 07, 2026 valued at $51.1k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $356,096.28. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.